Cardiol Therapeutics Inc. Class A Common Shares Stock Prediction
AI-powered sentiment analysis and prediction trends for CRDL, updated each market day.
CRDL AI Sentiment
AI sees no strong directional signal for Cardiol Therapeutics Inc. Class A Common Shares stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Cardiol Therapeutics Inc. Class A Common Shares
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
Exchange
Market Cap
$154,118,520
Cap Tier
Employees
18
Listed Since
Jan. 15, 2019
Website
CRDL Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
CRDL Volatility
Cardiol Therapeutics Inc. Class A Common Shares has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
